Search clinical trials for: NBI-98854 50 mg capsule

Total 1414 results

Neurocrine Biosciences

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

United States
Neurocrine Biosciences

Completed

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia (TD)

United States, Puerto Rico
Neurocrine Biosciences

Terminated

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Tardive Dyskinesia (TD)

United States, Puerto Rico
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
Neurocrine Biosciences

Terminated

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States
Neurocrine Biosciences

Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia (Kinect 4)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Neurocrine Biosciences

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome (T-FORCE)

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

Canada
Neurocrine Biosciences

Enrolling by invitation

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Chorea, Huntington

Canada
Neurocrine Biosciences
Huntington Study Group

Active, not recruiting

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Chorea, Huntington

United States, Canada
Neurocrine Biosciences

Completed

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Neurocrine Biosciences

Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Tourette Syndrome

United States
Neurocrine Biosciences

Completed

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Neurocrine Biosciences

Recruiting

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Tardive Dyskinesia | Major Depressive Disorder

United States
Neurocrine Biosciences

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

Cerebral Palsy | Dyskinesia

United States, Argentina, Poland, Spain
Zydus Lifesciences Limited

Recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
Neurocrine Biosciences
Huntington Study Group

Completed

Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease (KINECT-HD)

Chorea, Huntington

United States, Canada
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

Healthy
Neurocrine Biosciences

Completed

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

United States
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Johns Hopkins University
National Heart, Lung, and Blood Institute (NHLBI); American Lung Association

Completed

Pilot of Zinc Acetate to Improve Chronic Cough (ZICO)

Cough

United States
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
JLLC NatiVita
National Anti Doping Laboratory, Belarus

Not yet recruiting

The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Belarus
International Bio service

Not yet recruiting

Bioequivalence Study of Diacerein 50 mg Capsule in Healthy Thai Volunteers

Healthy Volunteer
Celgene

Completed

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

Healthy

United States
Boehringer Ingelheim

Completed

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Schizophrenia | Alzheimer Disease

United States
Neurocrine Biosciences

Recruiting

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Schizophrenia

United States, Bulgaria, Serbia
Neurocrine Biosciences

Terminated

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

Schizophrenia

United States
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Bod Australia
Woolcock Institute of Medical Research

Completed

The CANabidiol Use for RElief of Short Term Insomnia (CANREST)

Insomnia | Sleep Disturbance | Insomnia Type; Sleep Disorder | Insomnia, Transient | Insomnia Due to Anxiety and Fear | Insomnia Due to Other Mental Disorder

Australia
Federal Budgetary Research Institution State Research...

Completed

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Bloomage Biotechnology Corp., Ltd.

Completed

The Effect of Oral Hyaluronic Acid on the Skin

Healthy Japanese Subjects

Japan
Al-Mustafa University College

Recruiting

Colostrum Supplements Effect on the Physical Performance and Cognitive Function

Diabetes Mellitus, Type 2

Iraq
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in an ADULT Workplace Environment

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Boehringer Ingelheim

Completed

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Psoriasis

United States, Canada, Germany
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in Adolescent ADHD

ADHD

United States, Canada
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
University of California, San Francisco
San Francisco VA Health Care System

Completed

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD) (ACGT)

Alcohol Use Disorder

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

MItochondrial Myopathies

United States, Denmark

Search clinical trials for: NBI-98854 50 mg capsule

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations